Albumin: A Multi-talented Clinical and Pharmaceutical Player

다국어 초록 (Multilingual Abstract)

Albumin is one of the copious and important plasma proteins which takes an active part in transporting therapeutic agents, neutralization of toxins, protection from inflammation, and maintenance of colloidal intravascular osmotic pressure. Moreover, the albumin is also involved in modulating the acid-base balance, maintenance of vascular endothelial integrity, and binding to a range of exogenous and endogenous compounds. The binding capability of the albumin helps in the transportation, delivery, and clearance of drugs and compounds outside of the body. Due to the marked biological and biochemical properties, the albumin is used in critical care and other clinical conditions as a plasma volume expander, replacement of fluids and nutrients loss, and restoration of albumin levels in hypoalbuminemic individuals. Clinical and pharmaceutical scientists are studying it rigorously to address various pathological conditions. The use of human serum albumin in the management of diseased conditions still needs to be more clarified which can be done by following the institutional clinical guidelines established after the mutual consensus of the clinical experts belonging to different medical backgrounds. In this review, the evidence-based clinical utilization of the albumin in different pathological conditions like hemorrhagic shock, decompensated liver cirrhosis, sepsis and septic shock, abdominal and cardiac surgery, acute brain injury, acute respiratory distress syndrome, and Alzheimer’s disease has been discussed. Furthermore, in addition to the role of albumin in cell therapy, the special features of the albumin as a pharmaceutical vehicle like cancer-specific targeting capability, surface modifiability, stealth property, and its use as a formulation stabilizer have been reviewed.

참고문헌 (Reference)

• 1 Villeda, S. A., "Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice" 20 : 659-663, 2014
• 2 Taguchi, K., "When albumin meets liposomes: a feasible drug carrier for biomedical applications" 14 : 296-, 2021
• 3 Erstad, B. L., "Viral infectivity of albumin and plasma protein fraction" 16 : 996-1001, 1996
• 4 Katsimpardi, L., "Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors" 344 : 630-634, 2014
• 5 Kim, Y. S., "Update on Hsp90 inhibitors in clinical trial" 9 : 1479-1492, 2009
• 6 Sand, K. M. K, "Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics" 5 : 682-, 2015
• 7 Thongprayoon, C., "U-shape association of serum albumin level and acute kidney injury risk in hospitalized patients" 13 : e0199153-, 2018
• 8 Best, L. M., "Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network metaanalysis" 9 : CD013103-, 2019
• 9 Bern, M, "The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery" 211 : 144-162, 2015
• 10 Van Roy, M., "The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis" 17 : 135-, 2015
• 11 Quasney, M. W., "The outcomes of children with pediatric acute respiratory distress syndrome: proceedings from the Pediatric Acute Lung Injury Consensus Conference" 16 (16): S118-S131, 2015
• 12 Tucker, C., "The impact of criteria for use and a prescriber order from on albumin utilization" 8 : 255-258, 2017
• 13 Sindhwani, S., "The entry of nanoparticles into solid tumours" 19 : 566-575, 2020
• 14 "The effects of fluid balance and colloid administration on outcomes in patients with aneurysmal subarachnoid hemorrhage:a propensity score-matched analysis" 19 : 140-149,
• 15 Kobayashi, K., "The development of recombinant human serum albumin" 2 : 257-262, 1998
• 16 Vaglio, S., "The demand for human albumin in Italy" 11 (11): s26-s32, 2013
• 17 Caironi, P., "The clinical use of albumin:the point of view of a specialist in intensive care" 7 : 259-267, 2009
• 18 Sudlow, G., "The characterization of two specific drug binding sites on human serum albumin" 11 : 824-832, 1975
• 19 Costa, M., "The capacity of albumin to bind to beta-amyloid" 50 (50): S1-S4, 2010
• 20 Roche, M., "The antioxidant properties of serum albumin" 582 : 1783-1787, 2008
• 21 Spahn, D. R., "The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition" 23 : 98-, 2019
• 22 McLoughlin, G., "The British contribution to blood transfusion in the nineteenth century" 31 : 503-516, 1959
• 23 Schrader, J., "The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors" 34 : 1699-1703, 2003
• 24 Wong, F., "Terlipressin plus albumin for the treatment of type 1hepatorenal syndrome" 384 : 818-828, 2021
• 25 Fadaeian, G., "Targeted delivery of 5-fluorouracil with monoclonal antibody modified bovine serum albumin nanoparticles" 14 : 395-405, 2015
• 26 Fitzgerald, D. C., "Systemic inflammatory response during cardiac surgery: a pilot study" 10 : 125-132, 2015
• 27 Rhodes, A., "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016" 45 : 486-552, 2017
• 28 Jelenko, C., "Studies in shock and resuscitation, I: use of a hypertonic, albumincontaining, fluid demand regimen (HALFD) in resuscitation" 7 : 157-167, 1979
• 29 Carter, D. C., "Structure of serum albumin" 45 : 153-203, 1994
• 30 An, F.-F., "Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery" 7 : 3667-3689, 2017
• 31 Anderson, S. S., "Standardizing the use of albumin in large volume paracentesis" 33 : 420-424, 2020
• 32 Hawe, A., "Stabilization of a hydrophobic recombinant cytokine by human serum albumin" 96 : 2987-2999, 2007
• 33 Mirabel, C., "Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products" 16 : 291-, 2018
• 34 Liu, Z., "Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy" 45 : 1432-1456, 2016
• 35 Ascenzi, P., "Serum heme-albumin: an allosteric protein" 61 : 1118-1122, 2009
• 36 Finn, T. E., "Serum albumin prevents protein aggregation and amyloid formation and retains chaperone-like activity in the presence of physiological ligands" 287 : 21530-21540, 2012
• 37 Hornok, V., "Serum albumin nanoparticles: problems and prospects" 13 : 3759-, 2021
• 38 Zoellner, H., "Serum albumin is a specific inhibitor of apoptosis in human endothelial cells" 109 : 2571-2580, 1996
• 39 Peters, T., Jr., "Serum albumin" 37 : 161-245, 1985
• 40 Atwood, C. S., "Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins" 23 : 1343-1350, 2002
• 41 Sønderby, P., "Self-interaction of human serum albumin: a formulation perspective" 3 : 16105-16117, 2018
• 42 Du, W., "Self-assembly of bovine serum albumin and poly(acrylic acid) induced by noncovalent bonds" 127 : 4256-4261, 2013
• 43 Baldursdottir, S., "Screening of formulation parameters for stabilizing recombinant human serum albumin (rHSA) in liquid formulations" 34 : 1-9, 2016
• 44 Deane, R., "Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease" 4 : 191-197, 2007
• 45 Bertucci, C., "Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance" 9 : 1463-1481, 2002
• 46 Hsu, S.-L., "Retinoic acid-induced apoptosis is prevented by serum albumin and enhanced by Lipiodol in human hepatoma Hep3B cells" 129 : 205-214, 1998
• 47 Blanco-Schweizer, P., "Resuscitation with albumin using BET formula keeps at bay fluid administration in burned patients" 46 : 860-867, 2020
• 48 Tseng, C.-H., "Resuscitation fluid types in sepsis, surgical, and trauma patients: a systematic review and sequential network meta-analyses" 24 : 693-, 2020
• 49 Sahmeddini, M. A., "Restricted crystalloid fluid therapy during orthotopic liver transplant surgery and its effect on respiratory and renal insufficiency in the early post-operative period: a randomized clinical trial" 5 : 113-119, 2014
• 50 Rabin, J., "Restricted albumin utilization is safe and cost effective in a cardiac surgery intensive care unit" 104 : 42-48, 2017
• 51 Piano, S., "Response to terlipressin and albumin is associated with improved liver transplant outcomes in patients with hepatorenal syndrome" 73 : 1909-1919, 2021
• 52 Iglesias-López, C., "Regulatory framework for advanced therapy medicinal products in Europe and United States" 10 : 921-, 2019
• 53 Fakhry, S. M., "Regional and institutional variation in burn care" 16 : 86-90, 1995
• 54 Johnson, K. B., "Reduced albumin dosing during large-volume paracentesis is not associated with adverse clinical outcomes" 60 : 2190-2195, 2015
• 55 Chuang, V. T., "Recombinant human serum albumin" 43 : 547-561, 2007
• 56 Keenan, J., "Recombinant human albumin in cell culture: evaluation of growth-promoting potential for NRK and SCC-9 cells in vitro" 24 : 243-252, 1997
• 57 Tarelli, E., "Recombinant human albumin as a stabilizer for biological materials and for the preparation of international reference reagents" 26 : 331-346, 1998
• 58 Carpenter, J. F., "Rational design of stable lyophilized protein formulations:some practical advice" 14 : 969-975, 1997
• 59 Goodwin, C. W., "Randomized trial of efficacy of crystalloid and colloid resuscitation on hemodynamic response and lung water following thermal injury" 197 : 520-531, 1983
• 60 Skillman, J. J., "Randomized trial of albumin vs. electrolyte solutions during abdominal aortic operations" 78 : 291-303, 1975
• 61 Jeyachandran, Y. L., "Quantitative and qualitative evaluation of adsorption/desorption of bovine serum albumin on hydrophilic and hydrophobic surfaces" 25 : 11614-11620, 2009
• 62 Kamerzell, T. J., "Protein-excipient interactions:mechanisms and biophysical characterization applied to protein formulation development" 63 : 1118-1159, 2011
• 63 Frokjaer, S., "Protein drug stability: a formulation challenge" 4 : 298-306, 2005
• 64 Weil, D., "Prognosis of cirrhotic patients admitted to intensive care unit: a meta-analysis" 7 : 33-, 2017
• 65 Giguère, A., "Printed educational materials: effects on professional practice and healthcare outcomes" 8 : CD004398-, 2020
• 66 Brock, F., "Prevalence of hypoalbuminemia and nutritional issues in hospitalized elders" 24 : e2736-, 2016
• 67 Zhao, D., "Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles" 5 : 669-677, 2010
• 68 Lin, W., "Preparation of surface-modified albumin nanospheres" 18 : 559-565, 1997
• 69 Rungsakulkij, N., "Preoperative serum albumin is associated with intra-abdominal infection following major hepatectomy" 26 : 479-489, 2019
• 70 Kragh-Hansen, U., "Practical aspects of the ligand-binding and enzymatic properties of human serum albumin" 25 : 695-704, 2002
• 71 Meca-Lallana, J. E., "Plasmapheresis: its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study" 37 : 917-926, 2003
• 72 Bansch, P., "Plasma volume expansion with 5% albumin compared to Ringer's acetate during normal and increased microvascular permeability in the rat" 121 : 817-824, 2014
• 73 Zdolsek, M., "Plasma volume expansion and capillary leakage of 20%albumin in burned patients and volunteers" 24 : 191-, 2020
• 74 Kozar, R. A., "Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock" 112 : 1289-1295, 2011
• 75 Simonetti, R. G., "Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis" 6 : CD004039-, 2019
• 76 Boada, M, "Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: study design and progress" 5 : 61-69, 2019
• 77 Polidori, M. C., "Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia" 18 : 265-270, 2004
• 78 Gilgun-Sherki, Y., "Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence" 166 : 13-20, 2016
• 79 Bolling, C., "Phase II study of MTXHSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma" 24 : 521-527, 2006
• 80 Nanda, A., "Pharmacological therapies for hepatorenal syndrome: a systematic review and meta-analysis" 52 : 360-367, 2018
• 81 Zollner, S., "Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)" 12 : 220-228, 2014
• 82 Masich, A. M., "Pharmacokinetic/pharmacodynamic considerations of beta-lactam antibiotics in adult critically ill patients" 20 : 9-, 2018
• 83 Fujiwara, Y., "Perioperative serum albumin correlates with postoperative pancreatic fistula after pancreaticoduodenectomy" 35 : 499-503, 2015
• 84 Ishiwatari-Ogata, C., "Ozoralizumab, a humanized anti-TNFα NANOBODY®compound, exhibits efficacy not only at the onset of arthritis in a human TNF transgenic mouse but also during secondary failure of administration of an anti-TNFα IgG" 13 : 853008-, 2022
• 85 Sultana, R., "Oxidative modification of brain proteins in Alzheimer's disease: perspective on future studies based on results of redox proteomics studies" 33 (33): S243-S251, 2013
• 86 Nunomura, A, "Oxidative damage is the earliest event in Alzheimer disease" 60 : 759-767, 2001
• 87 Zhang, J., "Overview on acute-on-chronic liver failure" 10 : 1-17, 2016
• 88 Ghidini, M., "New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim" 12 : 1009-1015, 2016
• 89 Boada, M., "Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study" 18 : 1314-1324, 2022
• 90 Montine, T. J., "National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach" 123 : 1-11, 2012
• 91 Hyman, B. T., "National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease" 8 : 1-13, 2012
• 92 Fu, Q., "Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery" 4 : 262-272, 2009
• 93 Jokerst, J. V., "Nanoparticle PEGylation for imaging and therapy" 6 : 715-728, 2011
• 94 Nakamura, Y, "Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?" 27 : 2225-2238, 2016
• 95 Jack, C. R., Jr., "NIA-AA Research Framework: toward a biological definition of Alzheimer's disease" 14 : 535-562, 2018
• 96 Ezra, A., "Multifunctional effect of human serum albumin reduces Alzheimer's disease related pathologies in the 3xTg mouse model" 50 : 175-188, 2016
• 97 Halliwell, B., "Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?" 142 : 231-255, 2004
• 98 Ellmerer, M., "Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion" 278 : E352-E356, 2000
• 99 Zhao, J., "Mannitolum infusion on cirrhotic patients with tense ascites treated by paracentesis" 113 : 27-30, 2000
• 100 Cuberas-Borrós, G., "Longitudinal neuroimaging analysis in mild-moderate Alzheimer's disease patients treated with plasma exchange with 5% human albumin" 61 : 321-332, 2018
• 101 Caraceni, P., "Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial" 392 : 386-, 2018
• 102 Santagostino, E., "Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial" 127 : 1761-1769, 2016
• 103 Curry, S., "Lessons from the crystallographic analysis of small molecule binding to human serum albumin" 24 : 342-357, 2009
• 104 Park, C. H. L., "Lactated Ringer's versus 4% albumin on lactated Ringer's in early sepsis therapy in cancer patients: a pilot single-center randomized trial" 47 : e798-e805, 2019
• 105 Labgaa, I., "Is postoperative decrease of serum albumin an early predictor of complications after major abdominal surgery? A prospective cohort study in a European centre" 7 : e013966-, 2017
• 106 Kütting, F., "Insufficient evidence of benefit regarding mortality due to albumin substitution in HCC-free cirrhotic patients undergoing large volume paracentesis" 32 : 327-338, 2017
• 107 Wang, W, "Instability, stabilization, and formulation of liquid protein pharmaceuticals" 185 : 129-188, 1999
• 108 Du, G. -B., "Influences of different resuscitation regimens on acute early weight gain in extensively burned patients" 17 : 147-150, 1991
• 109 Kozek-Langenecker, S. A., "Influence of fluid therapy on the haemostatic system of intensive care patients" 23 : 225-236, 2009
• 110 Barbaro, B., "Increased albumin concentration reduces apoptosis and improves functionality of human islets. Artif. Cells Blood Substit" 36 : 74-81, 2008
• 111 Milojevic, J, "In vitro amyloid-β binding and inhibition of amyloid-β self-association by therapeutic albumin" 38 : 753-765, 2014
• 112 Keever-Taylor, C. A., "Improved cell viability, viable cell recovery and faster engraftment of products thawed using a premixed solution of human serum albumin and Dextran 40 compared to sequential addition during the thawing procedure" 116 : 2248-, 2010
• 113 Kinoshita, R., "Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer" 140 : 162-169, 2017
• 114 Elsadek, B., "Impact of albumin on drug delivery--new applications on the horizon" 157 : 4-28, 2012
• 115 SAFE Study Investigators, "Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis" 37 : 86-96, 2011
• 116 Lyu, P. F., "Impact of a sequential intervention on albumin utilization in critical care" 44 : 1307-1313, 2016
• 117 Wu, L.-T., "Illicit and nonmedical drug use among older adults: a review" 23 : 481-504, 2011
• 118 Spieker-Polet, H, "Identification of albumin as the serum factor essential for the growth of activated human lymphocytes" 251 : 987-992, 1976
• 119 Gibbert, K., "IFN-α subtypes: distinct biological activities in anti-viral therapy" 168 : 1048-1058, 2013
• 120 Sang, B.-H., "Hypoalbuminemia within two postoperative days is an independent risk factor for acute kidney injury following living donor liver transplantation: a propensity score analysis of 998consecutive patients" 43 : 2552-2561, 2015
• 121 Vincent, J. L., "Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials" 237 : 319-334, 2003
• 122 Wiedermann, C. J., "Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials" 14 : R191-, 2010
• 123 Myburgh, J. A., "Hydroxyethyl starch or saline for fluid resuscitation in intensive care" 367 : 1901-1911, 2012
• 124 Fanali, G., "Human serum albumin: from bench to bedside" 33 : 209-290, 2012
• 125 Milojevic, J., "Human serum albumin inhibits Abeta fibrillization through a "monomercompetitor"mechanism" 97 : 2585-2594, 2009
• 126 Chen, Z., "Human serum albumin from recombinant DNA technology: challenges and strategies" 1830 : 5515-5525, 2013
• 127 Stanyon, H. F., "Human serum albumin can regulate amyloid-β peptide fiber growth in the brain interstitium:implications for Alzheimer disease" 287 : 28163-28168, 2012
• 128 Shahin, H., "Human serum albumin as a clinically accepted cell carrier solution for skin regenerative application" 10 : 14486-, 2020
• 129 Suarez, J. I., "Human albumin use in adults in U.S. academic medical centers" 45 : e16-e22, 2017
• 130 Roberts, I., "Human albumin solution for resuscitation and volume expansion in critically ill patients" 2011 : CD001208-, 2011
• 131 Picón-Pagès, P., "Human albumin impairs amyloid β-peptide fibrillation through its C-terminus: from docking modeling to protection against neurotoxicity in Alzheimer's disease" 17 : 963-971, 2019
• 132 Fasano, M., "Heme binding to albuminoid proteins is the result of recent evolution" 59 : 436-440, 2007
• 133 Padmanabhan, A., "Guidelines on the use of therapeutic apheresis in clinical practice -evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue" 34 : 171-354, 2019
• 134 GBD 2016 Neurology Collaborators, "Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016" 18 : 459-480, 2019
• 135 Morton, P., "Formulation confidence with recombinant albumin: the benefits of a versatile stabiliser for challenging formulations" 24 : 12-15, 2019
• 136 Sun, Y, "Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy. Int. J. Nanomedicine" 14 : 135-148, 2019
• 137 Kingeter, A. J., "Fluids and organ dysfunction: a narrative review of the literature and discussion of 5 controversial topics" 32 : 2054-2066, 2018
• 138 Roopenian, D. C., "FcRn: the neonatal Fc receptor comes of age" 7 : 715-725, 2007
• 139 Song, X., "Experimental study on the efficacy of site-specific PEGylated human serum albumins in resuscitation from hemorrhagic shock" 44 : e1090-e1096, 2016
• 140 Ding, X., "Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice" 44 : 515-, 2006
• 141 Hanlon, P., "Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a crosssectional UK Biobank study" 8 : e018404-, 2018
• 142 Sakurai, Y., "Esterase-like activity of serum albumin: characterization of its structural chemistry using p-nitrophenyl esters as substrates" 21 : 285-292, 2004
• 143 Yano, Y., "Establishing a hospital transfusion management system promotes appropriate clinical use of human albumin in Japan: a nationwide retrospective study" 19 : 999-, 2019
• 144 Pennybaker, A., "Enhanced stability of cellbased products with recombinant human serum albumin in combination with an optimized inclusion of cryoprotective agents in a chemically defined cryoprotective media" 22 (22): S134-, 2020
• 145 Charpentier, J., "Efficacy and tolerance of hyperoncotic albumin administration in septic shock patients: the EARSS study" 37 (37): S115-, 2011
• 146 Boada, M., "Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-β concentrations and cognition outcomes in Alzheimer's disease patients: a multicenter, randomized, controlled clinical trial" 56 : 129-143, 2017
• 147 Blanloeil, Y., "Effects of plasma substitutes on hemostasis" 21 : 648-667, 2002
• 148 Huang, Z., "Effects of intravenous human albumin and furosemide on EEG recordings in patients with intracerebral hemorrhage" 113 : 454-458, 2002
• 149 Annane, D., "Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial" 310 : 1809-1817, 2013
• 150 Sort, P., "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis" 341 : 403-409, 1999
• 151 Navickis, R. J., "Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass:a meta-analysis of randomized trials" 144 : 223-230, 2012
• 152 Lee, E.-H., "Effect of exogenous albumin on the incidence of postoperative acute kidney injury in patients undergoing off-pump coronary artery bypass surgery with a preoperative albumin level of less than 4.0 g/dl" 124 : 1001-1011, 2016
• 153 Park, S. H., "Early albumin use improves mortality in difficult to resuscitate burn patients" 73 : 1294-1297, 2012
• 154 Chen, B., "Dual-peptide-functionalized albumin-based nanoparticles with ph-dependent self-assembly behavior for drug delivery" 7 : 15148-15153, 2015
• 155 Moore, D. C., "Drug-induced neutropenia: a focus on rituximab-induced late-onset neutropenia" 41 : 765-768, 2016
• 156 Qu, N., "Docetaxel-loaded human serum albumin (HSA) nanoparticles:synthesis, characterization, and evaluation" 18 : 11-, 2019
• 157 Bourdon, E., "Differential effects of cysteine and methionine residues in the antioxidant activity of human serum albumin" 39 : 15-20, 2005
• 158 Papadakou, P., "Determination of lymph flow in murine oral mucosa using depot clearance of near-infrared-labeled albumin" 425 : 97-101, 2015
• 159 Thakurta, S. G., "Design and Development of In Situ Albumin Binding Surfaces: Evaluation in the Paradigm of Blood-Biomaterial Compatibility" University of Nebraska - Lincoln 2010
• 160 Kim, T. S., "Decreased plasma antioxidants in patients with Alzheimer's disease" 21 : 344-348, 2006
• 161 Kratz, F., "DOXO-EMCH (INNO-206): the first albuminbinding prodrug of doxorubicin to enter clinical trials" 16 : 855-866, 2007
• 162 Jiaoyang Li ; 김휘 ; Md. Abdur Razzak ; 김은지 ; 최신식, "Crosslinker-free Bovine Serum Albumin-loaded Chitosan/alginate Nanocomplex for pH-responsive Bursting Release of Oral-administered Protein" 한국생물공학회 27 (27): 40-50, 2022
• 163 Fujita, T., "Control of in vivo fate of albumin derivatives utilizing combined chemical modification" 2 : 157-165, 1994
• 164 Chai, J.-K, "Consensus on use of albumin in burn patients" 37 : 755-, 2012
• 165 Moo-Young, M, "Comprehensive Biotechnology" Elsevier 2019
• 166 Skhirtladze, K., "Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer's lactate on blood loss and coagulation after cardiac surgery" 112 : 255-264, 2014
• 167 Ginés, P., "Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study" 93 : 234-241, 1987
• 168 Facciorusso, A., "Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis" 2 : 94-102, 2017
• 169 Skagen, C., "Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome" 43 : 680-685, 2009
• 170 Perel, P., "Colloids versus crystalloids for fluid resuscitation in critically ill patients" (6) : CD000567-, 2012
• 171 Garcovich, M., "Clinical use of albumin in hepatology" 7 : 268-277, 2009
• 172 Caraceni, P., "Clinical use of albumin" 11 (11): s18-s25, 2013
• 173 Buckley, M. S., "Clinical pharmacist-led impact on inappropriate albumin use and costs in the critically ill" 54 : 105-112, 2020
• 174 Caraceni, P., "Clinical indications for the albumin use: still a controversial issue" 24 : 721-728, 2013
• 175 de Wilde, S., "Clinical development of gene- and cell-based therapies:overview of the European landscape" 3 : 16073-, 2016
• 176 Cournand, A., "Chemical, clinical, and immunological studies on the products of human plasma fractionation. VIII. Clinical use of concentrated human serum albumin in shock, and comparison with whole blood and with rapid saline infusion" 23 : 491-505, 1944
• 177 Janeway, C. A., "Chemical, clinical, and immunological studies on the products of human plasma fractionation. VII. Concentrated human serum albumin" 23 : 465-490, 1944
• 178 Warren, J. V., "Chemical, clinical, and immunological studies on the products of human plasma fractionation. IX. The treatment of shock with concentrated human serum albumin: a preliminary report" 23 : 506-509, 1944
• 179 Rubio, L. A., "Characterization of pea (Pisum sativum) seed protein fractions" 94 : 280-287, 2014
• 180 Davis, D. A., "Changing physician performance. A systematic review of the effect of continuing medical education strategies" 274 : 700-705, 1995
• 181 Wierdak, M., "Changes in plasma albumin levels in early detection of infectious complications after laparoscopic colorectal cancer surgery with ERAS protocol" 32 : 3225-3233, 2018
• 182 Fanciullino, R., "Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs" 88 : 504-513, 2013
• 183 Nadim, M. K., "Cardiac and vascular surgery-associated acute kidney injury: the 20th international consensus conference of the ADQI (acute disease quality initiative) group" 7 : e008834-, 2018
• 184 Warden, G. D., "Burn shock resuscitation" 16 : 16-23, 1992
• 185 Bach, F. H., "Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome" 292 : 1364-1366, 1968
• 186 Hess, J. R., "Blood use in war and disaster: lessons from the past century" 43 : 1622-1633, 2003
• 187 McGuinness, B., "Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia" 2009 : CD004034-, 2009
• 188 Golchin, A., "Biological products:cellular therapy and FDA approved products" 15 : 166-175, 2019
• 189 Curry, S., "Beyond expansion: structural studies on the transport roles of human serum albumin" 83 (83): 315-319, 2002
• 190 Ivers, N., "Audit and feedback: effects on professional practice and healthcare outcomes" 6 : CD000259-, 2012
• 191 Trieu, V., "Antiangiogenic and antitumor activity of nanoparticle albumin bound (nab) thiocolchicine dimer (IDN5404) with a novel dual mechanism of action on Tubulin and Topoisomerase-1" 66 (66): 899-, 2006
• 192 Boada, M., "Amyloidtargeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization" 22 : 325-339, 2009
• 193 Kuo, Y.-M., "Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma" 268 : 750-756, 2000
• 194 Kurz, A., "Amyloid clearance as a treatment target against Alzheimer's disease" 24 (24): 61-73, 2011
• 195 Kauwe, G., "Amyloid beta emerges from below the neck to disable the brain" 19 : e3001388-, 2021
• 196 Pham, T. N., "American Burn Association practice guidelines burn shock resuscita" 29 : 257-266, 2008
• 197 Cankurtaran, M., "Altered levels of homocysteine and serum natural antioxidants links oxidative damage to Alzheimer's disease" 33 : 1051-1058, 2013
• 198 Ascenzi, P., "Allostery in a monomeric protein: the case of human serum albumin" 148 : 16-22, 2010
• 199 Azzazy, H. M. E., "All about albumin: biochemistry, genetics, and medical applications" Academic Press 432-, 1997
• 200 Peters, T., Jr, "All About Albumin: Biochemistry, Genetics and Medical Applications" Academic Press 1995
• 201 Rosenoer, V. M., "Albumin: Structure, Function and Uses" Elsevier 2014
• 202 Parastou Rahimizadeh ; 양성태 ; 임성인, "Albumin: An Emerging Opportunity in Drug Delivery" 한국생물공학회 25 (25): 985-995, 2020
• 203 Vega, L., "Albumin-blunted deleterious effect of amyloid-beta by preventing the internalization of the peptide into neurons" 17 : 795-805, 2009
• 204 Elzoghby, A. O., "Albumin-based nanoparticles as potential controlled release drug delivery systems" 157 : 168-182, 2012
• 205 Loureiro, A., "Albumin-based nanodevices as drug carriers" 22 : 1371-1390, 2016
• 206 Larsen, M. T., "Albumin-based drug delivery: harnessing nature to cure disease" 4 : 3-, 2016
• 207 Uhlig, C., "Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis" 18 : R10-, 2014
• 208 Charles, A., "Albumin use guidelines and outcome in a surgical intensive care unit" 143 : 935-939, 2008
• 209 Srouji, S., "Albumin supplementation to cold injection solution increases viability of endothelial and smooth muscle cells" 5 : 177-, 2014
• 210 Hunter, J. E., "Albumin resuscitation in burns: a hybrid regime to mitigate fluid creep" 2 : 2059513116-, 2016
• 211 Cooper, D. J., "Albumin resuscitation for traumatic brain injury: is intracranial hypertension the cause of increased mortality?" 30 : 512-518, 2013
• 212 Caironi, P., "Albumin replacement in patients with severe sepsis or septic shock" 370 : 1412-1421, 2014
• 213 Karimi, M., "Albumin nanostructures as advanced drug delivery systems" 13 : 1609-1623, 2016
• 214 Bernardi, M., "Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials" 55 : 1172-1181, 2012
• 215 Jackson, A., "Albumin in Medicine" Springer 121-145, 2016
• 216 Chaudhury, C., "Albumin binding to FcRn: distinct from the FcRn-IgG interaction" 45 : 4983-4990, 2006
• 217 Sethi, A., "Albumin as a drug delivery and diagnostic tool and its market approved products" 70 : 597-600, 2013
• 218 Kratz, F., "Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles" 132 : 171-183, 2008
• 219 Francis, G. L, "Albumin and mammalian cell culture:implications for biotechnology applications" 62 : 1-16, 2010
• 220 Haynes, G. R., "Albumin administration--what is the evidence of clinical benefit? A systematic review of randomized controlled trials" 20 : 771-793, 2003
• 221 Vincent, J. -L., "Albumin administration in the acutely ill: what is new and where next?" 18 : 630-, 2014
• 222 Dubois, M.-J., "Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study" 34 : 2536-2540, 2006
• 223 Eljaiek, R, "Albumin administration for fluid resuscitation in burn patients: a systematic review and meta-analysis" 43 : 17-24, 2017
• 224 Cordemans, C., "Aiming for a negative fluid balance in patients with acute lung injury and increased intra-abdominal pressure: a pilot study looking at the effects of PAL-treatment" 2 (2): S15-, 2012
• 225 Wang, W., "Advanced protein formulations" 24 : 1031-1039, 2015
• 226 Benedini, L., "Advanced protein drugs and formulations" 23 : 2-5, 2022
• 227 Comish, P., "Adoption of rescue colloid during burn resuscitation decreases fluid administered and restores end-organ perfusion" 47 : 1844-1850, 2021
• 228 Dong, V., "Acute-on-chronic liver failure: objective admission and support criteria in the intensive care unit" 1 : 44-52, 2019
• 229 Yoo, J., "Active targeting strategies using biological ligands for nanoparticle drug delivery systems" 11 : 640-, 2019
• 230 Swomley, A. M., "Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies" 1842 : 1248-1257, 2014
• 231 Domínguez-Prieto, M., "Aberrant co-localization of synaptic proteins promoted by Alzheimer's disease amyloid-β peptides:protective effect of human serum albumin" 55 : 171-182, 2017
• 232 Martin, R. H., "ALIAS (Albumin in Acute Ischemic Stroke) trials: analysis of the combined data from parts 1 and 2" 47 : 2355-2359, 2016
• 233 Buckle, T., "A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node" 21 : 355101-, 2010
• 234 Barros, C. P., "A revenue-neutral tax reform to increase demand for public transport services" 42 : 659-672, 2008
• 235 Martin, G. S., "A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury" 33 : 1681-1687, 2005
• 236 China, L., "A randomized trial of albumin infusions in hospitalized patients with cirrhosis" 384 : 808-817, 2021
• 237 O'Mara, M. S., "A prospective, randomized evaluation of intra-abdominal pressures with crystalloid and colloid resuscitation in burn patients" 58 : 1011-1018, 2005
• 238 Vermeulen, L. C., Jr, "A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions" 155 : 373-379, 1995
• 239 Mecocci, P., "A long journey into aging, brain aging, and Alzheimer's disease following the oxidative stress tracks" 62 : 1319-1335, 2018
• 240 Lang, T. C., "A critical update of the assessment and acute management of patients with severe burns" 8 : 607-633, 2019
• 241 Finfer, S., "A comparison of albumin and saline for fluid resuscitation in the intensive care unit" 350 : 2247-2256, 2004
• 242 Kratz, F., "A clinical update of using albumin as a drug vehicle - a commentary" 190 : 331-336, 2014
• 243 Hoelscher, V. S., "218 Impact of fresh frozen plasma infusions during resuscitation in thermally-injured patients" 39 (39): S76-, 2018